Metabolic dysfunction-associated steatohepatitis is a liver disease in which fat buildup and inflammation can damage the liver over time. Many people with metabolic dysfunction-associated steatohepatitis have no clear symptoms at first, but some feel tired or notice a dull ache on the right side of the belly. It often affects adults who have overweight or obesity, type 2 diabetes, or other features of metabolic syndrome, and early symptoms of metabolic dysfunction-associated steatohepatitis can be easy to miss. Not everyone will have the same experience, but this condition can last for years and may lead to scarring, liver failure, or liver cancer in some people. Treatment usually focuses on weight loss, regular exercise, healthier eating, and control of blood sugar, cholesterol, and blood pressure, and some people may also need medicines or specialist liver care.
How many people live with Metabolic dysfunction-associated steatohepatitis?
Worldwide, the broader fatty liver condition linked to metabolism is estimated to affect about 1.5 to 1.8 billion adults, and the inflamed form called MASH may affect about 100 to 400 million people; this is an estimate, not a direct count, and the range is wide because studies use different definitions and tests (AASLD Practice Guidance, 2023; United Nations, 2024). In the United States, about 60 million adults are estimated to have the broader condition, and about 4 to 17 million may have MASH (NIDDK, 2023; U.S. Census Bureau, 2024).
Overview
Metabolic dysfunction-associated steatohepatitisSymptoms
Metabolic dysfunction-associated steatohepatitis often causes no symptoms at first. When symptoms do appear, people may feel tired or notice a dull ache on the right side of the belly. Early symptoms of metabolic dysfunction-associated steatohepatitis can be easy to miss.
Outlook and prognosis
Metabolic dysfunction-associated steatohepatitis can improve, especially with weight loss, diabetes control, and limiting alcohol. Without treatment, some people develop liver scarring, cirrhosis, liver failure, or liver cancer, so regular follow-up matters.
Causes and risk factors
Metabolic dysfunction-associated steatohepatitis is most often linked to obesity, type 2 diabetes, insulin resistance, and high blood fats. Risk also rises with inactivity, sleep apnea, older age, and inherited tendency; rapid weight changes can worsen it.
Genetic influences
Genetics can influence who develops metabolic dysfunction-associated steatohepatitis and how quickly it worsens, but they are only one part of the picture. Many living with metabolic dysfunction-associated steatohepatitis also have important lifestyle and metabolic risk factors.
Diagnosis
Metabolic dysfunction-associated steatohepatitis is usually suspected from blood tests, imaging, and a review of alcohol use, medicines, and metabolic risk factors. The diagnosis of metabolic dysfunction-associated steatohepatitis may need a liver biopsy to confirm inflammation and scarring.
Treatment and drugs
Metabolic dysfunction-associated steatohepatitis is usually managed with weight loss, regular exercise, and treatment of diabetes, high cholesterol, or sleep apnea. Some people may also benefit from vitamin E, pioglitazone, or newer liver-focused medicines, depending on scarring and overall health.
Symptoms
Metabolic dysfunction-associated steatohepatitis, or MASH, often causes few or no symptoms at first, so it can be found only after blood tests or imaging done for something else. When symptoms do show up, they are often vague, such as low energy or discomfort on the upper right side of the belly. The changes are often subtle at first, blending into daily life until they become more noticeable. As liver damage becomes more advanced, symptoms can become clearer and more serious.
Many people with MASH feel well for a long time, especially in the early stages. In fact, early symptoms of metabolic dysfunction-associated steatohepatitis are often absent or so mild that they are easy to miss.
Ongoing tiredness or low energy is one of the more common symptoms people notice. What once felt effortless can start to require more energy or focus.
Some people feel a dull ache, pressure, or fullness under the right ribs, where the liver sits. It may come and go and can be easy to mistake for indigestion or a pulled muscle.
MASH can sometimes cause nausea, reduced appetite, or unplanned weight loss, especially as liver damage worsens. Day to day, it can feel like meals are less appealing or you get full sooner than usual.
How people usually first notice Metabolic dysfunction-associated steatohepatitis?
Metabolic dysfunction-associated steatohepatitis, or MASH, often stays quiet for years, so many people first find out after routine blood tests show elevated liver enzymes or an ultrasound done for another reason shows fat in the liver. When symptoms do appear, the first warning signs can be subtle, such as unusual tiredness, a dull ache or sense of fullness in the upper right side of the belly, or changes linked to the underlying metabolic problems that often travel with MASH, including weight gain, type 2 diabetes, or high cholesterol. Because these early signs are easy to miss, how people usually first notice MASH is often through a clinician connecting those test results with risk factors rather than from dramatic symptoms.
Types of Metabolic dysfunction-associated steatohepatitis
Metabolic dysfunction-associated steatohepatitis can affect people quite differently, especially as liver damage moves from mild inflammation to scarring. Symptoms don’t always look the same for everyone. Many living with metabolic dysfunction-associated steatohepatitis feel well for years, while others notice fatigue, vague discomfort, or later signs of more advanced liver disease. In practice, the main variations are based on disease stage, and symptoms often become more noticeable as scarring increases.
Early MASH
Early symptoms of metabolic dysfunction-associated steatohepatitis are often mild or absent. Some people feel unusually tired or notice a dull ache or pressure on the upper right side of the belly.
Fibrotic MASH
In this type, inflammation is joined by liver scarring, called fibrosis. People with metabolic dysfunction-associated steatohepatitis at this stage may still have few symptoms, but low energy, weakness, or ongoing discomfort can become more noticeable.
Cirrhotic MASH
This is the advanced form, where heavy scarring changes how the liver works. People may develop swelling in the legs or abdomen, easy bruising, itching, yellowing of the skin or eyes, or confusion, although not everyone will experience every type.
Compensated cirrhosis
At this stage, the liver is badly scarred but can still carry out many of its jobs. Many living with metabolic dysfunction-associated steatohepatitis have no clear day-to-day symptoms, or only fatigue and reduced stamina.
Decompensated cirrhosis
Here, the scarred liver can no longer keep up with the body’s needs. Symptoms are more serious and can include fluid buildup in the abdomen, vomiting blood, marked sleepiness, confusion, or severe weakness.
Can I slow down the onset of symptoms?
Partly yes: there is good evidence that healthy habits can lower the chance of metabolic dysfunction-associated steatohepatitis, or MASH, getting worse or starting to cause symptoms, but they cannot guarantee it will be prevented. The clearest factors linked to slower liver damage are reaching and keeping a healthier weight if needed, regular physical activity, a healthy eating pattern, good control of blood sugar, cholesterol, and blood pressure, and avoiding or limiting alcohol; these steps may reduce risk, but they do not erase it. There is no standard medicine proven to prevent MASH from starting, so regular medical follow-up to check liver health and treat related conditions early is the main medical approach, and while that can help, outcomes still vary from person to person.
What genetics can tell you about symptoms
Genetics can give some clues, but not a clear forecast, for people living with metabolic dysfunction-associated steatohepatitis. Certain inherited gene changes are linked to a higher chance of building up liver fat, developing more liver inflammation or scarring, and sometimes progressing at a younger age, which can make symptoms such as tiredness, belly discomfort, or signs of advanced liver disease more likely later on. Even so, genes do not reliably predict exactly which symptoms someone will have or how severe they will be, because weight, insulin resistance, alcohol use, other health conditions, and day-to-day lifestyle also play a big role.
Causes and risk factors
Metabolic dysfunction-associated steatohepatitis, or MASH, often starts when extra fat in the liver leads to inflammation and ongoing damage. It is more common in people with obesity, type 2 diabetes, insulin resistance, or high blood fats. Family history can be one part of the story, but lifestyle and environment add their own chapters. Eating a lot of added sugar or heavily processed foods, moving too little, and poor sleep can all make MASH more likely. Older age, sleep apnea, polycystic ovary syndrome, and some medicines are also risk factors for metabolic dysfunction-associated steatohepatitis.
What are the most common causes or risk factors?
The most common risk factors for metabolic dysfunction-associated steatohepatitis are extra body weight, especially around the waist, type 2 diabetes or prediabetes, high blood fats like triglycerides, high blood pressure, and not getting much physical activity, because these make it easier for fat to build up in the liver and cause swelling and damage. Risk is also higher in some people because it can run in families, and certain inherited gene changes can make the liver more likely to store fat and become damaged.
Environmental and biological risk factors
Metabolic dysfunction-associated steatohepatitis, or MASH, becomes more likely when fat builds up in the liver and the body is under ongoing metabolic strain. Doctors often group risks into internal (biological) and external (environmental). In practice, the main risk factors for metabolic dysfunction-associated steatohepatitis are body-based conditions that affect blood sugar, body fat, cholesterol, hormones, and sleep.
Insulin resistance and type 2 diabetes are among the strongest biological risk factors for MASH. When the body has trouble handling blood sugar, more fat can collect in the liver and inflammation is more likely.
Carrying excess body fat, especially around the waist, raises the chance of fat buildup in the liver. Abdominal fat is metabolically active, which means it can send more inflammatory signals to the liver.
High triglycerides and low good cholesterol often go hand in hand with metabolic dysfunction-associated steatohepatitis. These changes make it easier for fat to build up in the liver and harder for the liver to clear it.
When high blood pressure, raised blood sugar, abnormal cholesterol, and extra waist size cluster together, the risk of MASH goes up further. Having several of these problems at once often matters more than having just one.
Genetic risk factors
For many living with metabolic dysfunction-associated steatohepatitis, inherited traits can help explain why the liver stores fat, becomes inflamed, and may scar more easily. Some risk factors are inherited through our genes. The best-known genetic risk factors for metabolic dysfunction-associated steatohepatitis are common DNA changes in a few genes that affect how the liver handles fat, while family history can also point to a higher inherited tendency.
PNPLA3 gene: A change in the PNPLA3 gene is the strongest common inherited risk factor linked to MASH. It can make it easier for fat to build up in liver cells and harder for the liver to recover from injury. People who inherit two copies of the risk version often have a higher chance of inflammation and scarring.
TM6SF2 gene: A change in the TM6SF2 gene can affect how the liver packages and sends fat out into the blood. When that process is less efficient, more fat may stay in the liver and raise the risk of MASH and liver scarring.
MBOAT7 gene: Changes in the MBOAT7 gene are linked to a greater chance of liver inflammation and scarring in some people with MASH. Their effect is usually modest on its own, but it can add to risk alongside other inherited factors.
GCKR gene: Variants in the GCKR gene can push the liver to make and store more fat. This may increase the chance of fatty liver and, in some people, progression to MASH.
HSD17B13 gene: Certain changes in the HSD17B13 gene seem to lower the risk of liver inflammation and scarring. This helps explain why inherited traits can raise risk in some families but reduce it in others.
Family history: Having close relatives with fatty liver disease, cirrhosis, or MASH can suggest a higher inherited risk. It does not mean you will develop metabolic dysfunction-associated steatohepatitis, but it can be a useful clue when doctors assess risk.
Ancestry patterns: Some gene variants linked to MASH are more common in certain ancestral backgrounds, so average risk can differ between populations. People with the same risk factor can have very different experiences.
Lifestyle risk factors
Several everyday habits can increase the chance that metabolic dysfunction-associated steatohepatitis develops or becomes more severe. In practice, the most important lifestyle risk factors for metabolic dysfunction-associated steatohepatitis are patterns that promote insulin resistance, excess body fat, and ongoing liver inflammation. Diet, physical inactivity, alcohol use, and poor sleep all matter because they can worsen fat buildup in the liver and speed scarring over time.
Regularly eating more calories than the body uses can drive weight gain and increase fat storage in the liver. This makes liver inflammation and progression of metabolic dysfunction-associated steatohepatitis more likely.
Diets high in sugary drinks, refined carbohydrates, ultra-processed foods, and saturated fats can worsen insulin resistance and liver fat accumulation. Over time, this can increase the risk of steatohepatitis and fibrosis.
Physical inactivity reduces energy use and makes it harder to control body weight, blood sugar, and triglycerides. Too little exercise is one of the clearest examples of how lifestyle affects metabolic dysfunction-associated steatohepatitis because it can worsen liver fat and metabolic dysfunction.
Carrying excess abdominal fat is strongly linked to insulin resistance and a higher risk of liver inflammation. Larger waist size often signals a greater chance of MASH progressing to more advanced liver disease.
Risk prevention
Many people do not notice liver problems day to day until damage has built up, so lowering the risk of metabolic dysfunction-associated steatohepatitis often centers on protecting overall metabolic health early. The strongest steps are reaching a healthier weight if needed, staying active, and treating related problems such as type 2 diabetes, high cholesterol, and high blood pressure. Because early symptoms of metabolic dysfunction-associated steatohepatitis can be easy to miss, prevention works best when combined with regular check-ups. Metabolic dysfunction-associated steatohepatitis risk can often be reduced, even if some risks like family history are not changeable.
Gradual weight loss can lower liver fat, calm inflammation, and reduce the chance of metabolic dysfunction-associated steatohepatitis. For many adults, losing about 7% to 10% of body weight under medical guidance can make a meaningful difference.
Exercise helps the body use insulin better and can reduce liver fat even before major weight loss happens. Aim for steady activity most days, such as brisk walking, cycling, or strength training that fits your health and mobility.
Meals built around vegetables, fruit, beans, whole grains, nuts, fish, and less ultra-processed food can help protect the liver. Cutting back on sugary drinks, excess refined carbs, and large portions is especially helpful when metabolic dysfunction-associated steatohepatitis risk is tied to insulin resistance.
High blood sugar is a major driver of liver fat and liver injury. Keeping diabetes or prediabetes well controlled with food choices, activity, and prescribed treatment can lower the risk of metabolic dysfunction-associated steatohepatitis.
Can you prevent Metabolic dysfunction-associated steatohepatitis?
You cannot always fully prevent metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease, but many people can lower their risk. The most proven steps are keeping weight in a healthy range, staying physically active, and getting related health problems like type 2 diabetes, high cholesterol, and high blood pressure treated and well managed.
Transmission
Metabolic dysfunction-associated steatohepatitis, or MASH, is not infectious, so you cannot catch it from someone through coughing, kissing, sex, sharing food, or everyday contact. If you are wondering how metabolic dysfunction-associated steatohepatitis is transmitted, it is not spread person to person at all.
Instead, MASH develops inside the body when fat builds up in the liver and is linked with problems such as insulin resistance, type 2 diabetes, excess weight, and high cholesterol. MASH can sometimes seem to run in families because relatives may share genes and health risks, but this is not the same as being contagious.
When to test your genes
For metabolic dysfunction-associated steatohepatitis, genetic testing is not routinely recommended for early detection, because diagnosis and treatment are guided mainly by liver tests, imaging, and metabolic risk factors. It may be worth discussing if you have strong family history, unusually severe disease at a young age, or signs suggesting an inherited liver or iron disorder.
Diagnosis
Metabolic dysfunction-associated steatohepatitis, or MASH, is usually diagnosed after blood work or imaging suggests fat buildup and inflammation in the liver. Many people learn about it during a routine check-up because it often causes no clear symptoms at first, though some notice tiredness, discomfort on the right side of the belly, or abnormal liver tests. Doctors usually begin by looking at your symptoms, health history, and risk factors to understand whether MASH is likely and what else could be causing liver irritation. Some diagnoses are clear after a single visit, while others take more time.
Your doctor will ask about weight changes, diabetes, cholesterol, blood pressure, alcohol use, medicines, and family history. A detailed history helps sort out whether liver inflammation fits MASH or another liver condition.
The exam may include checking your weight, waist size, blood pressure, and looking for signs of liver disease. These findings cannot confirm MASH on their own, but they help show the bigger metabolic picture.
Liver enzyme tests can suggest liver irritation, while blood sugar, cholesterol, and triglyceride levels help show related metabolic problems. Other lab tests may help rule out common conditions such as viral hepatitis, autoimmune liver disease, or iron overload.
An ultrasound can show fat in the liver and may be the first imaging test used. It can support the diagnosis of MASH, but it cannot reliably show how much scarring is present.
How is Metabolic dysfunction-associated steatohepatitis diagnosed?
MASH is usually diagnosed by putting together your medical history, a physical exam, blood tests that look for liver damage and rule out other causes, and imaging tests such as an ultrasound or a special scan that can show fat and scarring in the liver. Many people with MASH feel fine or have only vague symptoms, so doctors also look for related health problems like type 2 diabetes, high cholesterol, or carrying extra weight. Sometimes a small liver sample, called a biopsy, is needed to confirm that there is both fat buildup and ongoing swelling and scarring, and genetic testing is not usually needed to make the diagnosis.
Stages of Metabolic dysfunction-associated steatohepatitis
Metabolic dysfunction-associated steatohepatitis is usually staged by how much scarring has built up in the liver, rather than by day-to-day symptoms alone. In the early symptoms of metabolic dysfunction-associated steatohepatitis, many people notice little or nothing, and the condition is often found on blood tests, imaging, or sometimes a liver biopsy. Sometimes answers come quickly, while other times it takes longer.
Stage 0
There is inflammation and fat in the liver, but no clear scar tissue yet. Many people with metabolic dysfunction-associated steatohepatitis feel well at this stage, even though liver damage has started.
Stage 1
Small areas of scar tissue begin to form, often around blood vessels in the liver. This is mild fibrosis, and lifestyle changes and treatment of related conditions can be especially important here.
Stage 2
Scar tissue becomes more noticeable and spreads to more parts of the liver. Metabolic dysfunction-associated steatohepatitis at this stage still may not cause obvious symptoms, but the risk of future liver problems is higher.
Stage 3
Scarring is widespread, but the liver can still do most of its jobs. People living with metabolic dysfunction-associated steatohepatitis may start to have more signs of liver strain, although some still feel few symptoms.
Stage 4
Severe scarring, known as cirrhosis, changes the liver's structure and can affect how well it works. At this stage, metabolic dysfunction-associated steatohepatitis can lead to complications such as fluid buildup, bleeding, confusion, or liver cancer.
Outlook and prognosis
The outlook for people with metabolic dysfunction-associated steatohepatitis varies widely, but it is generally less favorable when inflammation and scarring progress to advanced fibrosis or cirrhosis. Many people remain stable for years with effective weight loss, treatment of diabetes and other metabolic risk factors, and avoidance of excess alcohol, while others develop liver failure, portal hypertension, or hepatocellular carcinoma. The stage of fibrosis is the strongest predictor of long-term outcome, and patients with advanced fibrosis have a substantially higher risk of liver-related complications and death. Mortality is increased compared with the general population, with cardiovascular disease remaining a leading cause of death alongside liver-related causes and some cancers. Early diagnosis and sustained improvement in body weight, insulin resistance, and liver health can improve the prognosis and may even lead to regression of liver inflammation and fibrosis in some patients.
Long-term effects
For many people, metabolic dysfunction-associated steatohepatitis can stay quiet for years, then slowly lead to more serious liver damage. The long-term picture is often shaped by how much scarring builds up in the liver and whether related conditions like obesity, type 2 diabetes, or high cholesterol are also present. Some people remain stable for a long time, while others develop complications that affect both the liver and overall health. Thinking about the long-term effects helps explain why regular follow-up matters, even when early symptoms of metabolic dysfunction-associated steatohepatitis are mild or absent.
Ongoing inflammation can lead to fibrosis, which means scar tissue slowly replaces healthy liver tissue. In metabolic dysfunction-associated steatohepatitis, this scarring may worsen over time and can eventually become cirrhosis.
Once cirrhosis develops, the liver may have trouble doing its usual jobs, such as making proteins and clearing waste. Many living with advanced metabolic dysfunction-associated steatohepatitis can then develop fluid buildup in the belly, easy bruising, or confusion from toxins affecting the brain.
Severe, long-standing damage can cause the liver to stop working well enough to meet the body’s needs. This can mean jaundice, major swelling, bleeding problems, repeated hospital stays, and sometimes the need for a liver transplant.
Cirrhosis from metabolic dysfunction-associated steatohepatitis raises the risk of primary liver cancer, called hepatocellular carcinoma. This risk is highest once significant scarring is present, which is why doctors may track these changes over years to see when screening is needed.
How is it to live with Metabolic dysfunction-associated steatohepatitis?
Living with metabolic dysfunction-associated steatohepatitis can be surprisingly quiet at first, because many people feel little or nothing until fatigue, low energy, or a dull discomfort on the right side of the abdomen begins to affect daily life. For many, the bigger burden is the ongoing work around it: regular checkups, blood tests, imaging, and steady changes in eating habits, physical activity, weight, diabetes care, and alcohol avoidance, all while coping with the uncertainty of a liver condition that may slowly worsen over time. It can affect the people around you too, since partners and family members often help with appointments, lifestyle changes, and emotional support, but with good follow-up and shared routines, many people with MASH are able to take back a sense of control.
Treatment and drugs
Metabolic dysfunction-associated steatohepatitis, often shortened to MASH, is usually treated by improving the health problems that drive it, especially excess weight, insulin resistance or diabetes, high cholesterol, and high blood pressure. For many people, treatment begins with small daily steps, such as gradual weight loss, regular physical activity, and food changes that lower strain on the liver; avoiding or limiting alcohol is also commonly advised. Doctors sometimes recommend a combination of lifestyle changes and drugs, including medicines to help with weight loss or blood sugar control, and some people may be candidates for newer prescription treatment made specifically for MASH. Because scarring can range from mild to advanced, treatment plans are tailored to how much liver damage is present and to other conditions a person may have. If you are looking into the best treatment for metabolic dysfunction-associated steatohepatitis, regular follow-up matters, since blood tests, scans, and symptom checks help show whether the liver is improving or whether the plan needs to change.
Can you cure Metabolic dysfunction-associated steatohepatitis?
There is not one simple cure for metabolic dysfunction-associated steatohepatitis, a more serious form of fatty liver disease, but it can often improve a lot and may even reverse, especially when it is found early. Treatment focuses on weight loss if needed, regular exercise, healthier eating, and treating related problems like type 2 diabetes, high cholesterol, and high blood pressure; for some people, medicine may also help lower liver inflammation and slow or prevent scarring.
Non-drug treatment
For many, treatment begins not at the pharmacy, but with daily habits that lower liver fat and calm inflammation. In metabolic dysfunction-associated steatohepatitis, or MASH, the main non-drug treatments focus on weight loss, movement, food choices, and treating related problems such as sleep apnea and high blood sugar. Even a modest weight loss can help, and larger losses often bring bigger liver benefits, though the plan needs to be realistic and safe. Not every approach works the same way, so care is usually tailored to your liver health, weight, and other conditions.
Gradual weight loss is the cornerstone of care for many people with metabolic dysfunction-associated steatohepatitis. Losing about 5% to 10% of body weight often helps reduce liver fat and inflammation, and some may need more for scarring to improve.
A Mediterranean-style eating pattern, with vegetables, beans, whole grains, nuts, fish, and olive oil, is often recommended for MASH. Cutting back on sugary drinks, highly processed foods, and large portions can make a meaningful difference over time.
Aerobic activity and strength training can both help lower liver fat, even before much weight comes off. A practical goal is at least 150 minutes a week of moderate activity, such as brisk walking, cycling, or swimming, plus muscle-strengthening work on 2 days a week.
Working with a dietitian, health coach, or structured weight-management program can make changes easier to stick with. This is often one of the most helpful parts of diet and exercise for metabolic dysfunction-associated steatohepatitis because it turns advice into a plan that fits real life.
Your genes may have an impact on how drugs work for you
For people living with metabolic dysfunction-associated steatohepatitis, or MASH, small inherited differences can change how the body breaks down certain medicines, which may affect how well a treatment works or how likely side effects are. This can matter not only for newer treatments aimed at liver disease, but also for common medicines used alongside MASH, such as drugs for diabetes, weight, or cholesterol, so one person may improve more while another may need a different dose or a different option. Even so, gene-based drug matching, sometimes called pharmacogenomics, is not yet a routine part of MASH care, and treatment decisions are still based mostly on liver health, weight, blood sugar, cholesterol, and how someone responds over time.
Pharmacological treatments
Treatment for metabolic dysfunction-associated steatohepatitis often focuses on lowering liver inflammation, reducing fat in the liver, and treating related problems such as type 2 diabetes, high cholesterol, or obesity. Right now, the main medicine specifically approved for some adults with metabolic dysfunction-associated steatohepatitis is resmetirom, while several other drugs are used off-label in carefully selected people. Not everyone responds to the same medication in the same way. In practice, medicines are usually chosen based on liver scarring, diabetes status, body weight, and the risk of side effects.
Resmetirom is a newer prescription drug approved for certain adults with metabolic dysfunction-associated steatohepatitis who have liver scarring but not cirrhosis. It helps lower liver fat and can improve inflammation and fibrosis, which matter when treating early symptoms of metabolic dysfunction-associated steatohepatitis and slowing disease progression. Doctors usually monitor liver tests, thyroid-related labs, and cholesterol during treatment.
Pioglitazone is a diabetes medicine that can also improve liver inflammation in some people with metabolic dysfunction-associated steatohepatitis, especially those who also have type 2 diabetes. It is not approved specifically for MASH, but it is widely used off-label in specialist care. Possible downsides include weight gain, fluid retention, and a higher risk of fractures in some people.
Vitamin E may help reduce liver inflammation in some adults with metabolic dysfunction-associated steatohepatitis who do not have diabetes. It is usually considered when liver biopsy or specialist assessment suggests active disease. Long-term use is not right for everyone, so the dose and risks should be reviewed with a clinician.
Semaglutide and liraglutide are medicines used for type 2 diabetes and weight loss, and they can help by lowering body weight and liver fat. Many living with metabolic dysfunction-associated steatohepatitis also have obesity or diabetes, so these drugs may be part of treatment even though they are not yet approved specifically for MASH. Common side effects include nausea, vomiting, and diarrhea, especially when starting or increasing the dose.
Genetic influences
When liver tests stay abnormal or a scan shows extra fat in the liver, many people living with metabolic dysfunction-associated steatohepatitis wonder whether it runs in the family. It’s natural to ask whether family history plays a role. In MASH, genetics can influence how the liver handles fat and how strongly it responds with inflammation and scarring, and inherited variants in genes such as PNPLA3 and TM6SF2 can raise the chance of disease. These inherited factors do not act alone, though, because insulin resistance, body weight, type 2 diabetes, diet, alcohol use, and other health conditions also play major roles. So, a higher genetic risk for MASH does not mean someone will definitely develop it, and people with no known family history can still be affected. If several close relatives have fatty liver disease, cirrhosis, or early symptoms of MASH, telling your doctor can help shape screening, treatment, and decisions about whether family members should also be checked.
Is Metabolic dysfunction-associated steatohepatitis genetic?
Genetics can influence who develops metabolic dysfunction-associated steatohepatitis and how quickly it worsens, but they are only one part of the picture. Many living with metabolic dysfunction-associated steatohepatitis also have important lifestyle and metabolic risk factors.
Having a genetic risk is not necessarily a diagnosis
Changes in genes are a normal part of being human and are widely seen in the general population. Most of these variants do not directly affect health and simply reflect natural differences among people. For many genes, having a variant connected to a condition suggests a possible link rather than a certain diagnosis, especially when several genes and environmental factors are involved. In some situations, though, one well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
For many living with metabolic dysfunction-associated steatohepatitis, treatment is still guided much more by liver scarring, weight, diabetes, cholesterol, and other health conditions than by a genetic test. Some inherited gene changes can make MASH more likely to become severe, but they do not yet reliably tell doctors which medicine for MASH will work best or be safest. Not every difference in response is genetic, but genes may partly affect how the liver handles medicines and how likely some people are to have side effects, especially when several drugs are used together. That means genetics is not yet a routine part of choosing treatment for metabolic dysfunction-associated steatohepatitis, even though researchers are studying whether it could help predict treatment response in the future. For now, if you are wondering about genetic influences on MASH treatment, doctors mainly rely on scan or biopsy results, blood tests, and your overall metabolic health to guide care.
Interactions with other conditions
People living with metabolic dysfunction-associated steatohepatitis often also have conditions tied to metabolism, especially type 2 diabetes, overweight or obesity, high blood pressure, and abnormal cholesterol levels. Day-to-day, it can feel like one health issue amplifies the other, because insulin resistance and ongoing inflammation can worsen liver damage while liver disease can make blood sugar and fat levels harder to control. Metabolic dysfunction-associated steatohepatitis is also linked with a higher risk of heart and blood vessel disease, which is a major part of overall health planning. Some may also have sleep apnea, polycystic ovary syndrome, or chronic kidney disease, and these can add to fatigue, strain on the body, or treatment complexity. If cirrhosis develops, the liver may no longer handle medicines, alcohol, or infections as well, so even common illnesses can become more serious. Talk with your doctor about how your conditions may influence each other, especially if you have early symptoms of metabolic dysfunction-associated steatohepatitis or are being treated for diabetes or heart disease at the same time.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Metabolic dysfunction-associated steatohepatitis?
Metabolic dysfunction-associated steatohepatitis can look a lot like other liver and belly problems, especially simple fatty liver, alcohol-related liver disease, hepatitis B or C, liver irritation from some medicines, gallbladder disease, and sometimes liver conditions caused by the body’s immune system. Because the signs are often mild, such as tiredness, feeling unwell, or a dull ache on the upper right side of the belly, these conditions can be easy to mix up, so doctors usually use blood tests, imaging, and sometimes other liver tests to tell them apart.
History
For many people living with metabolic dysfunction-associated steatohepatitis, the condition can feel very modern, tied to today’s concerns about weight, blood sugar, and heart health. But doctors have been describing fatty changes and inflammation in the liver for much longer than most people realize. Earlier reports focused on what was seen under the microscope or during surgery, long before the condition had its current name.
In recent decades, awareness has grown as researchers recognized that some people with extra fat in the liver were not just storing fat but also developing ongoing irritation and injury. For years, this problem was often grouped under older terms, especially “nonalcoholic steatohepatitis,” or NASH. As medical science evolved, experts moved toward the newer name metabolic dysfunction-associated steatohepatitis to better reflect what is driving it in many cases: a mix of liver fat, inflammation, and metabolic health problems such as insulin resistance, obesity, abnormal cholesterol, or type 2 diabetes.
That shift in language matters because names shape how conditions are understood. The older wording mainly emphasized what the disease was not, while the newer term points more clearly to the body-wide metabolic changes linked with liver damage. This has helped doctors think more broadly about care, including blood sugar, blood pressure, cholesterol, and weight, not only the liver itself.
The history of metabolic dysfunction-associated steatohepatitis is also a story of better detection. In the past, many people had no clear symptoms, or they were told they simply had mildly abnormal liver tests. Someone might have gone in for a routine blood test or an ultrasound for another reason and only then learned there was concern about liver inflammation. Over time, doctors came to understand that early symptoms of metabolic dysfunction-associated steatohepatitis can be subtle, and that some people can develop scarring of the liver even without feeling very sick at first.
Research has continued to refine who is at risk, how the disease progresses, and how best to diagnose and treat it. Understandings have changed, but the overall picture is now much clearer: metabolic dysfunction-associated steatohepatitis is a serious form of fatty liver disease that deserves attention, support, and follow-up care. For patients and families, this history helps explain why the condition may have been overlooked in the past and why it is now being recognized more openly and treated more proactively.